PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027
The Pharma Data
FEBRUARY 8, 2021
RE47,739 (‘739) by more than four years until March 5, 2027. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis.
Let's personalize your content